|
1
|
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang
X and Wang L: Down-regulation of miR-183 promotes migration and
invasion of osteosarcoma by targeting Ezrin. Am J Pathol.
180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated
autophagy as a novel therapeutic strategy for osteosarcoma.
Autophagy. 8:275–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang E, Kim L, Choi JM, Park SE, Rhee EJ,
Lee WY, Oh KW, Park SW, Park DI and Park CY: Ezetimibe stimulates
intestinal glucagon-like peptide 1 secretion via the MEK/ERK
pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism.
64:633–641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q,
Chen J, Chen X, Zhang S, Liu Z, et al: miR-137 targets Cdc42
expression, induces cell cycle G1 arrest and inhibits invasion in
colorectal cancer cells. Int J Cancer. 128:1269–1279. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen L, Wang X, Wang H, Li Y, Yan W, Han
L, Zhang K, Zhang J, Wang Y, Feng Y, et al: miR-137 is frequently
down-regulated in glioblastoma and is a negative regulator of
Cox-2. Eur J Cancer. 48:3104–3111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Croce C: Introduction to the role of
microRNAs in cancer diagnosis, prognosis and treatment. Cancer J.
18:213–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang C, Yao C, Li H, Wang G and He X:
Combined elevation of microRNA-196a and microRNA-196b in sera
predicts unfavorable prognosis in patients with osteosarcomas. Int
J Mol Sci. 15:6544–6555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong Q, Fang J, Pang Y and Zheng J:
Prognostic value of the microRNA-29 family in patients with primary
osteosarcomas. Med Oncol. 31:372014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu LH, Li H, Li JP, Zhong H, Zhang HC,
Chen J and Xiao T: miR-125b suppresses the proliferation and
migration of osteosarcoma cells through down-regulation of STAT3.
Biochem Bioph Res Commun. 416:31–38. 2011. View Article : Google Scholar
|
|
11
|
Osaki M, Takeshita F, Sugimoto Y, Kosaka
N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T,
et al: MicroRNA-143 regulates human osteosarcoma metastasis by
regulating matrix metalloprotease-13 expression. Mol Ther.
19:1123–1130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Y, Liu H, Li Y, Wu J, Greenlee AR,
Yang C and Jiang Y: The role of miR-506 in transformed 16HBE cells
induced by anti-benzo[a]pyrene-trans-7, 8-dihydrodiol-9,
10-epoxide. Toxicol Lett. 205:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arora H, Qureshi R and Park WY: miR-506
regulates epithelial mesenchymal transition in breast cancer cell
lines. PloS One. 8:e642732013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM,
Xiao SD and Ran ZH: MicroRNA 506 regulates expression of PPAR alpha
in hydroxycamptothecin-resistant human colon cancer cells. FEBS
Lett. 585:3560–3568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He W, He S, Wang Z, Shen H, Fang W, Zhang
Y, Qian W, Lin M, Yuan J, Wang J, et al: Astrocyte elevated gene-1
(AEG-1) induces epithelial-mesenchymal transition in lung cancer
through activating Wnt/β-catenin signaling. BMC Cancer. 15:1072015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Emdad L, Sarkar D, Su ZZ, Randolph A,
Boukerche H, Valerie K and Fisher PB: Activation of the nuclear
factor kappaB pathway by astrocyte elevated gene-1: Implications
for tumor progression and metastasis. Cancer Res. 66:1509–1516.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoo BK, Emdad L, Su ZZ, Villanueva A,
Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet
JM, et al: Astrocyte elevated gene-1 regulates hepatocellular
carcinoma development and progression. J Clin Invest. 119:465–477.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu C, Chen K, Zheng H, Guo X, Jia W, Li M,
Zeng M, Li J and Song L: Overexpression of astrocyte elevated
gene-1 (AEG-1) is associated with esophageal squamous cell
carcinoma (ESCC) progression and pathogenesis. Carcinogenesis.
30:894–901. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu B, Wu Y and Peng D: Astrocyte elevated
gene-1 regulates osteosarcoma cell invasion and chemoresistance via
endothelin-1/endothelin A receptor signaling. Oncol Lett.
5:505–510. 2013.PubMed/NCBI
|
|
21
|
Wang F, Ke Z-F, Sun SJ, Chen WF, Yang SC,
Li SH, Mao XP and Wang LT: Oncogenic roles of astrocyte elevated
gene-1 (AEG-1) in osteosarcoma progression and prognosis. Cancer
Biol Ther. 12:539–548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang F, Ke ZF, Wang R, Wang YF, Huang LL
and Wang LT: Astrocyte elevated gene-1 (AEG-1) promotes
osteosarcoma cell invasion through the JNK/c-Jun/MMP-2 pathway.
Biochem Bioph Res Commun. 452:933–939. 2014. View Article : Google Scholar
|
|
23
|
Schajowicz F: World Health Organization:
Histological Typing of Bone Tumours (2nd). Springer-Verlag. Berlin:
1993.
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Song X, Liu C, Xie L, Wei L and Sun
R: Knockdown of astrocyte elevated gene-1 inhibits proliferation
and enhancing chemo-sensitivity to cisplatin or doxorubicin in
neuroblastoma cells. J Exp Clin Cancer Res. 28:192009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guan H, Tan P, Xie L, Mi B, Fang Z, Li J,
Yue J, Liao H and Li F: FOXO1 inhibits osteosarcoma oncogenesis via
Wnt/β-catenin pathway suppression. Oncogenesis. 4:e1662015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang C, Yao C, Li H, Wang G and He X:
Serum levels of microRNA-133b and microRNA-206 expression predict
prognosis in patients with osteosarcoma. Int J Clin Exp Pathol.
7:4194–4203. 2014.PubMed/NCBI
|
|
28
|
Ma W, Zhang X, Chai J, Chen P, Ren P and
Gong M: Circulating miR-148a is a significant diagnostic and
prognostic biomarker for patients with osteosarcoma. Tumor Biol.
35:12467–12472. 2014. View Article : Google Scholar
|
|
29
|
Huang K, Li LA, Meng Y, You Y, Fu X and
Song L: High expression of astrocyte elevated gene-1 (AEG-1) is
associated with progression of cervical intraepithelial neoplasia
and unfavorable prognosis in cervical cancer. World J Surg Oncol.
11:2972013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kikuno N, Shiina H, Urakami S, Kawamoto K,
Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M and Dahiya
R: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer
progression through upregulation of FOXO3a activity. Oncogene.
26:7647–7655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y,
Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K,
et al: MiR-506 inhibits multiple targets in the
epithelial-to-mesenchymal transition network and is associated with
good prognosis in epithelial ovarian cancer. J Pathol. 235:25–36.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang
D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, et al:
MiR-506 suppresses proliferation and induces senescence by directly
targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol.
233:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs
JJ, Gitelis S, O'Keefe RJ, Konttinen YT, Yin G and Li TF:
Inhibition of the Wnt-β-catenin and Notch signaling pathways
sensitizes osteosarcoma cells to chemotherapy. Biochem Bioph Res
Commun. 431:274–279. 2013. View Article : Google Scholar
|
|
35
|
Hoang BH, Kubo T, Healey JH, Yang R,
Nathan SS, Kolb EA, Mazza B, Meyers PA and Gorlick R: Dickkopf 3
inhibits invasion and motility of Saos-2 osteosarcoma cells by
modulating the Wnt-beta-catenin pathway. Cancer Res. 64:2734–2739.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q,
Zuo G, Zhou L, Weng Y, Tang M, et al: Dihydroartemisinin inhibits
tumor growth of human osteosarcoma cells by suppressing
Wnt/β-catenin signaling. Oncol Rep. 30:1723–1730. 2013.PubMed/NCBI
|
|
37
|
Lv Z, Wang C, Yuan T, Liu Y, Song T, Liu
Y, Chen C, Yang M, Tang Z, Shi Q and Weng Y: Bone morphogenetic
protein 9 regulates tumor growth of osteosarcoma cells through the
Wnt/β-catenin pathway. Oncol Rep. 31:989–994. 2014.PubMed/NCBI
|
|
38
|
Xia JJ, Pei LB, Zhuang JP, Ji Y, Xu GP,
Zhang ZP, Li N and Yan JL: Celecoxib inhibits β-catenin-dependent
survival of the human osteosarcoma MG-63 cell line. J Int Med Res.
38:1294–1304. 2010. View Article : Google Scholar : PubMed/NCBI
|
